



---

## Zedira Presents Clinical Candidate for Celiac Disease Therapy

Chicago and Darmstadt, Sep. 23 2009

---

In course of the Chicago Celiac Disease Conference preclinical data has been presented supporting the selection of Zedira's novel Transglutaminase blocker ZED-101 as clinical candidate for the treatment of celiac disease.

Blocking tissue transglutaminase is a promising therapeutic option in celiac disease. Zedira developed rationally designed peptidomimetic blockers bearing a michael acceptor pharmacophore. The safety profile and selectivity over other transglutaminase isoenzymes make ZED-101 an optimal candidate for subsequent clinical development.

Zedira considers either out-licensing ZED-101 to a pharmaceutical company or further conducting preclinical and clinical trials backed by investors.

### About celiac disease

Epidemiological studies proved a prevalence of celiac disease of approximately 1% in Europe and North America but also in other countries. It is a common, life-long inflammatory and autoimmune disease affecting the small intestine. Susceptible individuals mount an immune response to specific gluten derived peptides. Gluten is a protein fraction found in common dietary food grains such as wheat, barley and rye.

Once gluten peptides reach the gut, they are deamidated by tissue transglutaminase (TG2) triggering a chronic inflammatory response.

So far no pharmacological therapy is available for celiac disease patients, thus forcing them to follow a restrictive and expensive gluten free diet.

### About Zedira

Zedira, a biotech company located in Darmstadt, Germany, has made a commitment to celiac disease and transglutaminase. The company markets products for research and development as well as for diagnostics. In Zedira's therapeutic branch the proprietary small molecule transglutaminase blockers provide the basis for a drug development pipeline with celiac disease as lead indication.

---

For additional information, please visit the company's website or contact us

#### Zedira GmbH

Martin Hils PhD  
Roesslerstr. 83  
64293 Darmstadt  
Germany

phone	+49 6151 325110
fax	+49 6151 325119
e-mail	<a href="mailto:contact@zedira.com">contact@zedira.com</a>
web	<a href="http://www.zedira.com">www.zedira.com</a>